PUMA BIOTECHNOLOGY, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that PUMA BIOTECHNOLOGY, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $21.61M | Mar 9, 2018 |
| FY2017 | Sep 30, 2017 | $6.08M | Mar 9, 2018 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $228.37M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $230.47M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $235.64M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $228.03M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $253.16M | Feb 29, 2024 |
| FY2020 | Dec 31, 2020 | $52.56M | Mar 1, 2021 |
| FY2020 | Sep 30, 2020 | $50.75M | Mar 1, 2021 |
| FY2020 | Jun 30, 2020 | $70.58M | Mar 1, 2021 |
| FY2020 | Mar 31, 2020 | $51.22M | Mar 1, 2021 |
| FY2020 | Dec 31, 2019 | $62.92M | Mar 1, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $31.11M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $30.28M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $21.59M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $2.0K | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | ($29.13M) | Feb 29, 2024 |
| FY2020 | Dec 31, 2020 | ($14.99M) | Mar 1, 2021 |
| FY2020 | Sep 30, 2020 | ($31.46M) | Mar 1, 2021 |
| FY2020 | Jun 30, 2020 | $3.40M | Mar 1, 2021 |
| FY2020 | Mar 31, 2020 | ($16.93M) | Mar 1, 2021 |
| FY2020 | Dec 31, 2019 | ($11.20M) | Mar 1, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $37.30M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $30.97M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $32.64M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $23.72M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $1.29M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | ($30.40M) | Mar 2, 2023 |
| FY2021 | Dec 31, 2019 | ($39.05M) | Mar 3, 2022 |
| FY2020 | Dec 31, 2018 | ($94.66M) | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | ($292.39M) | Feb 28, 2020 |
| FY2018 | Dec 31, 2016 | ($276.60M) | Mar 1, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $71.87M | Mar 3, 2022 |
| FY2021 | Dec 31, 2020 | $97.65M | Mar 3, 2022 |
| FY2021 | Dec 31, 2019 | $132.85M | Mar 3, 2022 |
| FY2020 | Dec 31, 2018 | $164.85M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $207.81M | Feb 28, 2020 |
| FY2018 | Dec 31, 2016 | $222.80M | Mar 1, 2019 |
| FY2017 | Dec 31, 2015 | $208.47M | Mar 9, 2018 |
| FY2016 | Dec 31, 2014 | $122.92M | Mar 1, 2017 |
| FY2015 | Dec 31, 2013 | $45.05M | Feb 29, 2016 |
| FY2014 | Dec 31, 2012 | $49.64M | Mar 2, 2015 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $70.85M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $80.16M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $89.93M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $89.98M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $116.29M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $118.49M | Mar 2, 2023 |
| FY2021 | Dec 31, 2019 | $141.64M | Mar 3, 2022 |
| FY2020 | Dec 31, 2018 | $146.17M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $106.69M | Feb 28, 2020 |
| FY2018 | Dec 31, 2016 | $53.80M | Mar 1, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $41.80M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $38.92M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $27.01M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | ($15.83M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $20.65M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $773.0K | Mar 2, 2023 |
| FY2021 | Dec 31, 2019 | $22.38M | Mar 3, 2022 |
| FY2020 | Dec 31, 2018 | ($24.11M) | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | ($172.47M) | Feb 28, 2020 |
| FY2018 | Dec 31, 2016 | ($141.69M) | Mar 1, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $71.0K | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $56.0K | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $140.0K | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $0 | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $0 | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $46.0K | Mar 2, 2023 |
| FY2021 | Dec 31, 2019 | $306.0K | Mar 3, 2022 |
| FY2018 | Dec 31, 2018 | $439.0K | Mar 1, 2019 |
| FY2018 | Dec 31, 2017 | $431.0K | Mar 1, 2019 |
| FY2018 | Dec 31, 2016 | $4.29M | Mar 1, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $216.30M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $213.33M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $230.53M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $222.06M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $226.59M | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | $244.22M | Mar 3, 2022 |
| FY2020 | Dec 31, 2019 | $234.91M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $259.12M | Feb 28, 2020 |
| FY2018 | Dec 31, 2017 | $165.53M | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | $252.79M | Mar 9, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $85.96M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $121.21M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $177.09M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $200.45M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $229.03M | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | $250.17M | Mar 3, 2022 |
| FY2020 | Dec 31, 2019 | $217.44M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $224.82M | Feb 28, 2020 |
| FY2018 | Dec 31, 2017 | $112.22M | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | $42.97M | Mar 9, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $130.34M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $92.13M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $53.44M | Feb 26, 2026 |
| FY2025 | Dec 31, 2022 | $21.61M | Feb 26, 2026 |
| FY2024 | Dec 31, 2021 | ($2.45M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2020 | ($5.95M) | Feb 29, 2024 |
| FY2022 | Dec 31, 2019 | $17.46M | Mar 2, 2023 |
| FY2021 | Dec 31, 2018 | $34.31M | Mar 3, 2022 |
| FY2020 | Dec 31, 2017 | $53.30M | Mar 1, 2021 |
| FY2019 | Dec 31, 2016 | $209.82M | Feb 28, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.28B) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($1.31B) | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | ($1.35B) | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | ($1.37B) | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | ($1.37B) | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | ($1.34B) | Mar 3, 2022 |
| FY2020 | Dec 31, 2019 | ($1.28B) | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | ($1.20B) | Feb 28, 2020 |
| FY2018 | Dec 31, 2017 | ($1.09B) | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | ($796.51M) | Mar 9, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $29.64M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $69.22M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $84.59M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $76.20M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $63.13M | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | $85.29M | Mar 3, 2022 |
| FY2020 | Dec 31, 2019 | $60.04M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $108.42M | Feb 28, 2020 |
| FY2018 | Dec 31, 2017 | $81.70M | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | $194.49M | Mar 9, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $22.68M | Feb 26, 2026 |
| FY2024 | Dec 31, 2024 | $68.00M | Feb 27, 2025 |
| FY2023 | Dec 31, 2023 | $102.00M | Feb 29, 2024 |
| FY2022 | Dec 31, 2022 | $102.00M | Mar 2, 2023 |
| FY2021 | Dec 31, 2021 | $102.00M | Mar 3, 2022 |
| FY2020 | Dec 31, 2020 | $84.03M | Mar 1, 2021 |
| FY2019 | Dec 31, 2019 | $94.96M | Feb 28, 2020 |
| FY2019 | Dec 31, 2018 | $151.89M | Feb 28, 2020 |
| FY2018 | Dec 31, 2017 | $48.48M | Mar 1, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Feb 29, 2024 |
| FY2020 | Dec 31, 2020 | 0 | Mar 1, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Mar 1, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Mar 1, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Mar 1, 2021 |
| FY2021 | Dec 31, 2019 | (75,595) | Mar 3, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Feb 29, 2024 |
| FY2020 | Dec 31, 2020 | 0 | Mar 1, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Mar 1, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Mar 1, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Mar 1, 2021 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 50.41M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 49.11M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | 47.65M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | 46.35M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | 41.18M | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | 40.09M | Mar 3, 2022 |
| FY2020 | Dec 31, 2019 | 39.20M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | 38.33M | Feb 28, 2020 |
| FY2018 | Dec 31, 2017 | 37.59M | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | 36.83M | Mar 9, 2018 |